TY - JOUR
T1 - Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in the Netherlands
AU - Henry, Thea L.
AU - De Brouwer, Bonnie F E
AU - Van Keep, Marjolijn M L
AU - Blankestijn, Peter J.
AU - Bots, Michiel L.
AU - Koffijberg, Hendrik
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objectives:Safety and efficacy data for catheter-based renal denervation (RDN) in the treatment of resistant hypertension have been used to estimate the cost-effectiveness of this approach. However, there are no Dutch-specific analyses. This study examined the cost-effectiveness of RDN from the perspective of the healthcare payer in The Netherlands.Methods:A previously constructed Markov state-transition model was adapted and updated with costs and utilities relevant to the Dutch setting. The cost-effectiveness of RDN was compared with standard of care (SoC) for patients with resistant hypertension. The efficacy of RDN treatment was modeled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure (SBP).Results: Treatment with RDN compared to SoC gave an incremental quality-adjusted life year (QALY) gain of 0.89 at an additional cost of €1315 over a patient's lifetime, resulting in a base case incremental cost-effectiveness ratio (ICER) of €1474. Deterministic and probabilistic sensitivity analyses (PSA) showed that treatment with RDN therapy was cost-effective at conventional willingness-to-pay thresholds (€10,000-80,000/QALY).Conclusion: RDN is a cost-effective intervention for patients with resistant hypertension in The Netherlands.
AB - Objectives:Safety and efficacy data for catheter-based renal denervation (RDN) in the treatment of resistant hypertension have been used to estimate the cost-effectiveness of this approach. However, there are no Dutch-specific analyses. This study examined the cost-effectiveness of RDN from the perspective of the healthcare payer in The Netherlands.Methods:A previously constructed Markov state-transition model was adapted and updated with costs and utilities relevant to the Dutch setting. The cost-effectiveness of RDN was compared with standard of care (SoC) for patients with resistant hypertension. The efficacy of RDN treatment was modeled as a reduction in the risk of cardiovascular events associated with a lower systolic blood pressure (SBP).Results: Treatment with RDN compared to SoC gave an incremental quality-adjusted life year (QALY) gain of 0.89 at an additional cost of €1315 over a patient's lifetime, resulting in a base case incremental cost-effectiveness ratio (ICER) of €1474. Deterministic and probabilistic sensitivity analyses (PSA) showed that treatment with RDN therapy was cost-effective at conventional willingness-to-pay thresholds (€10,000-80,000/QALY).Conclusion: RDN is a cost-effective intervention for patients with resistant hypertension in The Netherlands.
KW - Cardiovascular disease
KW - Cost-effectiveness
KW - Prevention
KW - Renal sympathetic denervation
KW - Resistant hypertension
UR - http://www.scopus.com/inward/record.url?scp=84918784608&partnerID=8YFLogxK
U2 - 10.3111/13696998.2014.978453
DO - 10.3111/13696998.2014.978453
M3 - Article
C2 - 25367314
AN - SCOPUS:84918784608
SN - 1369-6998
VL - 18
SP - 76
EP - 87
JO - Journal of Medical Economics
JF - Journal of Medical Economics
IS - 1
ER -